Biotech China 2014

View Profile


Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors
1. 2013 Multilevel models for cost-effectiveness analyses that use cluster randomised trial data: An approach to model choice Statistical methods in medical research 2013; :
2. 2012 Methods For Covariate Adjustment In Cost‐Effectiveness Analysis That Use Cluster Randomised Trials Health economics 2012; 21:1101-1118
3. 2012 Developing appropriate methods for cost-effectiveness analysis of cluster randomized trials Medical Decision Making 2012; 32:350-361
4. 2012 Statistical Methods for Cost-Effectiveness Analyses That Use Data from Cluster Randomized Trials A Systematic Review and Checklist for Critical Appraisal Medical Decision Making 2012; 32:209-220
5. 2010 Bayesian hierarchical models for cost-effectiveness analyses that use data from cluster randomized trials Medical Decision Making 2010; 30:163-175
6. 2010 Non‐parametric methods for cost‐effectiveness analysis: the central limit theorem and the bootstrap compared Health economics 2010; 19:316-333
7. 2009 The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation Pharmaceutical statistics 2009; 8:371-389
8. 2009 Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta‐analytical approach International journal of clinical practice 2009; 63:766-775
9. 2009 Cost‐Effectiveness of Disease‐Modifying Therapies in the Management of Multiple Sclerosis for the Medicare Population Value in Health 2009; 12:657-665
10. 2009 Using short‐term evidence to predict six‐month outcomes in clinical trials of signs and symptoms in rheumatoid arthritis Pharmaceutical statistics 2009; 8:150-162
11. 2008 Biologic drugs for rheumatoid arthritis in the medicare program: A cost‐effectiveness analysis Arthritis & Rheumatism 2008; 58:939-946
12. 2007 Estimating the rates of disability progression in people with active relapsing-remitting multiple sclerosis Journal of Medical Economics 2007; 10:79-89
13. 2007 The efficacy of inhibiting tumour necrosis factor α and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons Rheumatology 2007; 46:1140-1147
14. 2007 Using mixed treatment comparisons and meta‐regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis Statistics in medicine 2007; 26:1237-1254
15. 2007 Modelling the cost effectiveness of TNF-α antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry Rheumatology 2007; 46:1345-1354
16. 2007 The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK Value in health 2007; 10:54-60
17. 2007 Multilevel models for estimating incremental net benefits in multinational studies Health economics 2007; 16:815-826
18. 2007 The distribution of the cost of multiple sclerosis in the UK: how do costs vary by illness severity? Value in Health 2007; 10:386-389
19. 2006 Addressing the issues that arise in analysing multicentre cost data, with application to a multinational study Journal of health economics 2006; 25:1015-1028
20. 2006 Costs and quality of life of multiple sclerosis in Italy The European Journal of Health Economics 2006; 7:45-54
21. 2006 Indicators of undernutrition in cattle Animal Welfare 2006; 15:149-160
22. 2006 Costs and quality of life of multiple sclerosis in the United Kingdom The European Journal of Health Economics 2006; 7:96-104
23. 2005 Methods for incorporating covariate adjustment, subgroup analysis and between‐centre differences into cost‐effectiveness evaluations Health economics 2005; 14:1217-1229
24. 2005 How sensitive are cost-effectiveness analyses to choice of parametric distributions? Medical Decision Making 2005; 25:416-423
25. 2005 Implications for the human food chain of models of cadmium accumulation in sheep Environmental research 2005; 97:348-358
26. 2005 Using multilevel models for assessing the variability of multinational resource use and cost data Health economics 2005; 14:185-196
27. 2005 Parametric modelling of cost data: some simulation evidence Health economics 2005; 14:421-428
28. 2004 Parametric modelling of cost data in medical studies Statistics in medicine 2004; 23:1311-1331
29. 2004 Meta-analysis of feeding trials investigating cadmium accumulation in the livers and kidneys of sheep Environmental research 2004; 94:171-183
30. 2003 Imputation of a true endpoint from a surrogate: application to a cluster randomized controlled trial with partial information on the true endpoint BMC medical research methodology 2003; 3:17
31. 2003 Baseline adjustments for binary data in repeated cross‐sectional cluster randomized trials Statistics in medicine 2003; 22:2673-2692
32. 2003 Bayesian evaluation of breast cancer screening using data from two studies Statistics in medicine 2003; 22:1661-1674
33. 2002 A comparison of clinical assessment with ultrasound in the management of secondary postpartum haemorrhage European Journal of Obstetrics & Gynecology and Reproductive Biology 2002; 104:113-115
34. 2002 Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations British journal of cancer 2002; 86:218-221
35. 2002 Cross-issue synthesis: potential application to breast cancer, tamoxifen and genetic susceptibility. Journal of cancer epidemiology and prevention 2002; 7:205
36. 2002 Estimates of the likely prophylactic with high risk BRCA1 and BRCA2 effect of tamoxifen in women mutations BRITISH JOURNAL OF CANCER 2002; 86:218-221
37. 2001 Randomization at the level of primary care practice: use of pre‐intervention data and random effects models Statistics in medicine 2001; 20:1727-1738
38. 2001 Evidence that longer androgen receptor polyglutamine repeats are a causal factor for genital abnormalities Journal of Clinical Endocrinology & Metabolism 2001; 86:3207-3210
39. 2001 Initial results of a study into the effectiveness of breast cancer screening in a population identified to be at high risk. Revue d'épidémiologie et de santé publique 2001; 49:471-475
40. 2001 Premiers resultats d'une etude sur l'efficacite d'un programme de depistage du cancer du sein chez les femmes ayant un risque familial Revue d'Epidemiologie et de Sante Publique 2001; 49:471-476
41. 2000 Longer polyglutamine tracts in the androgen receptor are associated with moderate to severe undermasculinized genitalia in XY males Human molecular genetics 2000; 9:829-834
42. 2000 Mammographic screening in women with a family history of breast cancer: some results from the Swedish two-county trial. Revue d'épidémiologie et de santé publique 2000; 48:325-331
43. 1999 Some random-effects models for the analysis of matched-cluster randomised trials: application to the Swedish two-county trial of breast-cancer screening. Journal of epidemiology and biostatistics 1999; 5:349-358
44. 1999 Randomised controlled trial of educational package on management of menorrhagia in primary care: the Anglia menorrhagia education study BMJ 1999; 318:1246-1250
45. 1999 An audit of menorrhagia management in primary care in East Anglia: the Anglia menorrhagia education study. BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY 1999; 106:1103-1103


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.